Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
290
-0.13%
|
$68,150
$235.39 P/Share
|
|
Feb 10
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,518
-5.35%
|
$833,766
$237.74 P/Share
|
|
Feb 10
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,040
-3.83%
|
$720,480
$237.74 P/Share
|
|
Feb 10
2022
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,437
-4.28%
|
$577,569
$237.74 P/Share
|
|
Feb 10
2022
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,031
-2.14%
|
$718,347
$237.74 P/Share
|
|
Feb 10
2022
|
Joy Liu SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
474
-2.76%
|
$112,338
$237.74 P/Share
|
|
Feb 10
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,491
-4.05%
|
$590,367
$237.74 P/Share
|
|
Feb 10
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
979
-1.78%
|
$232,023
$237.74 P/Share
|
|
Feb 10
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,230
-2.08%
|
$291,510
$237.74 P/Share
|
|
Feb 10
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,434
-4.24%
|
$576,858
$237.74 P/Share
|
|
Feb 02
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,660
-0.97%
|
$1,169,660
$251.08 P/Share
|
|
Feb 02
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,660
+6.21%
|
$400,760
$86.52 P/Share
|
|
Feb 02
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
6,279
-5.38%
|
$1,525,797
$243.63 P/Share
|
|
Feb 02
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,040
-0.37%
|
$262,080
$252.61 P/Share
|
|
Feb 02
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,944
-4.88%
|
$736,000
$250.07 P/Share
|
|
Feb 01
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,108
+16.68%
|
-
|
|
Feb 01
2022
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,566
+39.32%
|
-
|
|
Feb 01
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
38,375
+16.46%
|
-
|
|
Feb 01
2022
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
23,988
+13.62%
|
-
|
|
Feb 01
2022
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
67,949
+16.01%
|
-
|
|
Feb 01
2022
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
66,817
+19.03%
|
-
|
|
Feb 01
2022
|
Joy Liu SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,941
+17.74%
|
-
|
|
Feb 01
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
29,638
+16.23%
|
-
|
|
Feb 01
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
526
-0.93%
|
$127,818
$243.64 P/Share
|
|
Feb 01
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
BUY
Grant, award, or other acquisition
|
Direct |
23,942
+19.36%
|
-
|
|
Feb 01
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
27,714
+15.34%
|
-
|
|
Feb 01
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,588
+14.04%
|
-
|
|
Jan 28
2022
|
Margaret G Mcglynn Director |
SELL
Open market or private sale
|
Direct |
5,000
-31.95%
|
$1,210,000
$242.1 P/Share
|
|
Jan 28
2022
|
Margaret G Mcglynn Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.05%
|
$635,000
$127.54 P/Share
|
|
Nov 15
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
34
-0.05%
|
$6,358
$187.15 P/Share
|
|
Nov 15
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
3
-0.0%
|
$561
$187.4 P/Share
|
|
Nov 15
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
51
-0.08%
|
$9,537
$187.13 P/Share
|
|
Nov 01
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
766
-2.3%
|
$141,710
$185.07 P/Share
|
|
Aug 19
2021
|
Reshma Kewalramani CEO & President |
BUY
Open market or private purchase
|
Direct |
10,000
+6.54%
|
$1,950,000
$195.74 P/Share
|
|
Aug 02
2021
|
Bruce I Sachs Director |
BUY
Open market or private purchase
|
Direct |
15,000
+26.69%
|
$2,955,000
$197.91 P/Share
|
|
Jul 30
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
766
-2.25%
|
$153,200
$200.39 P/Share
|
|
Jun 02
2021
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
559
-3.34%
|
$116,831
$209.99 P/Share
|
|
Jun 01
2021
|
Margaret G Mcglynn Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
699
-38.88%
|
-
|
|
May 28
2021
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
311
-0.93%
|
$65,310
$210.04 P/Share
|
|
May 17
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
79
-0.08%
|
$17,064
$216.25 P/Share
|
|
May 17
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
109
-0.09%
|
$23,544
$216.28 P/Share
|
|
May 17
2021
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
112
-0.67%
|
$24,192
$216.42 P/Share
|
|
May 17
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
45
-0.04%
|
$9,720
$216.42 P/Share
|
|
May 17
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
112
-0.16%
|
$24,192
$216.42 P/Share
|
|
May 03
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
960
-1.38%
|
$209,280
$218.45 P/Share
|
|
May 01
2021
|
Sangeeta N. Bhatia Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,842
+24.26%
|
-
|
|
May 01
2021
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,842
+25.43%
|
-
|
|
May 01
2021
|
Margaret G Mcglynn Director |
BUY
Grant, award, or other acquisition
|
Direct |
921
+33.87%
|
-
|
|
May 01
2021
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,842
+35.98%
|
-
|
|
Apr 30
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
766
-2.14%
|
$166,222
$217.21 P/Share
|